Epizyme
Epizyme - Personalized Therapeutics & The Power of Epigenetics.
Launch date
Employees
Market cap
AUD236m
Enterprise valuation
AUD385m (Public information from Aug 2022)
Share price
$1.47 EPZM
Cambridge Massachusetts (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 19.1m | 20.9m | 13.6m | 48.2m | 67.3m |
| % growth | - | - | - | 10 % | (35 %) | 253 % | 40 % |
| EBITDA | - | - | (115m) | (160m) | (201m) | (196m) | (199m) |
| % EBITDA margin | - | - | (605 %) | (765 %) | (1473 %) | (408 %) | (296 %) |
| Profit | - | - | (113m) | (157m) | (211m) | (205m) | (193m) |
| % profit margin | - | - | (590 %) | (752 %) | (1547 %) | (425 %) | (286 %) |
| EV / revenue | - | - | 11.8x | 82.4x | 63.9x | 4.6x | 3.3x |
| EV / EBITDA | - | - | -1.9x | -10.8x | -4.3x | -1.1x | -1.1x |
| R&D budget | 79.0m | 83.0m | 73.0m | 97.0m | - | - | - |
| R&D % of revenue | - | - | 382 % | 464 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Series A | ||
$32.0m | Series B | ||
$8.0m | Series B | ||
$7.5m | Early VC | ||
$4.0m | Early VC | ||
| N/A | N/A | IPO | |
$10.0m | Post IPO Equity | ||
* | N/A | $173m | Post IPO Equity |
* | $270m | Growth Equity VC | |
* | $247m | Acquisition | |
| Total Funding | AUD497m | ||
Related Content
Recent News about Epizyme
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.